Eindhoven, the Netherlands-based company said that, combined with $55 million raised at the end of 2025, the latest funding demonstrates investor confidence in its strategy and strengthens its ability to execute on clinical, regulatory and commercial objectives as it works to bring its vascular access technology to the U.S.
aXess, the company’s restorative vascular access conduit, is designed to enable the creation of a new, permanent, living vessel for hemodialysis vascular access. It combines the safety and patency of arteriovenous fistula (AVF) with the speed to treatment of arteriovenous grafts (AVG). The conduit aims to deliver an improved dialysis patient experience while avoiding reinterventions and complications like infections.
Xeltis began commercial activity for aXess earlier this month. It plans to use proceeds from the latest funding to finalize its ongoing U.S. pivotal trial for aXess. Funds will then support its FDA submission and its go-to-market strategy in the U.S. Xeltis also expects to use some funds to support its European rollout and a manufacturing scale-up, plus continued pipeline advancement.
New investor Horizon 3 Healthcare led the round for Xeltis. Participants included the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita and other current shareholders.
Eliane Schutte, CEO, Xeltis, said:
“This fundraising not only enables us to bring our groundbreaking vascular access technology to more European patients, as we continue our successful commercial rollout, but also enables us to advance our aXess pivotal trial in the US, prepare for US market launch and continue our other exciting clinical programs, XABG and XPAD. We welcome our new investor Horizon 3 Healthcare and thank them, and our existing investors, for their confidence in Xeltis as we look to bring much-needed alternatives to patients.”
